Biotie Therapies - Annual Financial Report

Biotie's Annual Financial Report and Corporate Governance Statement 2011 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 8 March 2012 at 9.00 a.m.

Biotie's Annual Financial Report and Corporate Governance Statement 2011
published

Biotie Therapies Corp.' s  Annual financial report for the financial period
ended 31 December 2011 as well as Corporate Governance Statement 2011 have been
published.

The documents are attached in pdf format in this release. Both documents are
also available at Biotie's website www.biotie.com in English and Finnish
language.

Turku, 8 March 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.

The company has a strong and balanced development portfolio with several
innovative small molecule and biological drug candidates at different stages of
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential.

Partnerships with top-tier pharmaceutical partners are in place for several
programs as well as a strategic collaboration with UCB Pharma S.A. The Marketing
Authorization Application for Biotie's most advanced product, Selincro(TM)
(nalmefene) for alcohol dependence was filed in the EU by our partner H.
Lundbeck A/S and was accepted for review by the European Medicines Agency in
December 2011.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.


[HUG#1592175]

Liitteet:

Biotie_Corporate Governance Statement 2011.pdf

Biotie_Financial Statements 2011.pdf